Aclaris Therapeutics Inc. (NASDAQ:ACRS) had its price target lifted by Jefferies Group from $23.00 to $31.00 in a research report released on Monday. The firm currently has a buy rating on the stock.

Several other equities research analysts have also commented on ACRS. Zacks Investment Research lowered shares of Aclaris Therapeutics from a hold rating to a sell rating in a report on Tuesday, May 24th. Guggenheim assumed coverage on shares of Aclaris Therapeutics in a report on Friday, June 10th. They issued a buy rating and a $35.00 price target for the company. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $31.25.

Aclaris Therapeutics (NASDAQ:ACRS) opened at 24.50 on Monday. The company’s market cap is $524.67 million. The company’s 50-day moving average is $21.21 and its 200-day moving average is $19.73. Aclaris Therapeutics has a 12 month low of $10.99 and a 12 month high of $33.88.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Thursday, August 11th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.01. On average, equities research analysts expect that Aclaris Therapeutics will post ($2.61) EPS for the current fiscal year.

In other news, insider Kamil Ali-Jackson sold 3,738 shares of Aclaris Therapeutics stock in a transaction that occurred on Friday, August 26th. The shares were sold at an average price of $20.35, for a total value of $76,068.30. Following the transaction, the insider now owns 20,289 shares of the company’s stock, valued at approximately $412,881.15. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Ra Capital Management, Llc sold 525,550 shares of Aclaris Therapeutics stock in a transaction that occurred on Friday, September 16th. The stock was sold at an average price of $24.19, for a total transaction of $12,713,054.50. The disclosure for this sale can be found here. 46.40% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Vivo Capital LLC purchased a new position in shares of Aclaris Therapeutics during the first quarter worth about $79,427,000. FIL Ltd purchased a new position in shares of Aclaris Therapeutics during the second quarter worth about $13,801,000. Vanguard Group Inc. increased its position in shares of Aclaris Therapeutics by 147.6% in the second quarter. Vanguard Group Inc. now owns 419,184 shares of the company’s stock worth $7,743,000 after buying an additional 249,888 shares during the last quarter. BlackRock Fund Advisors increased its position in shares of Aclaris Therapeutics by 59.7% in the second quarter. BlackRock Fund Advisors now owns 234,696 shares of the company’s stock worth $4,335,000 after buying an additional 87,739 shares during the last quarter. Finally, State Street Corp increased its position in shares of Aclaris Therapeutics by 64.8% in the second quarter. State Street Corp now owns 120,010 shares of the company’s stock worth $2,217,000 after buying an additional 47,179 shares during the last quarter. 71.39% of the stock is currently owned by hedge funds and other institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.

5 Day Chart for NASDAQ:ACRS

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.